The conditioning regimens for autologous SCT (auto-SCT) lead to impairment of the immune system and concomitant increase in susceptibility to infections. We studied the recovery of cellular immunity by in vitro analysis of T-cell proliferation and cytokine production profiles during the first 15 months after auto-SCT in patients with multiple myeloma and non-Hodgkin's lymphoma. PBMC were collected at 6, 9 and 15 months after transplantation and stimulated with a combination of CD2 and CD28 monoclonal antibodies, with PHA or with tetanus toxoid as recall antigen. A multiplex enzyme linked immunoassay was used to determine levels of QJ;Th1 cytokines IL-2, IFN-c and tumour-necrosis factor-a (TNFa), Th2 cytokines IL-4, IL-5 and IL-13, the regulatory cytokine IL-10 and the proinflammatory cytokines IL-1a, IL-1b, IL-6 and the chemokine IL-8. T-cell proliferation progressively increased from 6 to 15 months after auto-SCT. Overall, cytokine production increased after auto-SCT. Production of Th2 cytokines IL-5 and IL-13 was superior to production of Th1 cytokines IFN-c and TNF-a. We hypothesize that prolonged impairment of IFN-c production might contribute to the relatively high incidence of viral infections after auto-SCT.
Introduction
High-dose chemotherapy followed by autologous peripheral SCT (auto-SCT) is a widely used therapy for many haematological malignancies.
1,2 High-dose chemotherapy destroys malignant cells, whereas SCT rescues the otherwise fatal pancytopenia. Although peripheral SCT is believed to shorten the early period of severe neutropenia as compared to bone marrow transplantation, 3 the functional capacity of the immune system remains partially impaired for a year or even longer after transplantation. [4] [5] [6] The impairment of the immune system in the first period after auto-SCT is reflected in the high incidence of infectious complications, which is a major source of morbidity. 7, 8 B lymphocyte numbers in peripheral blood normalize within 6-12 months after auto-SCT, but the capacity to mount an adequate antibody response to vaccination is low until 6 months after transplantation and gradually improves thereafter. 9, 10 Several studies on the quantitative development of cellular immunity after auto-SCT found normal or even high levels of natural killer cells 2 weeks after transplantation. [4] [5] [6] T lymphocyte numbers, however, remain low for a substantial longer period. 11 High-dose chemotherapy will destroy most T cells in the recipient. Following transplantation, stem cells present in the graft will develop into mature T cells as in normal ontogeny including maturation in the thymus. 5, 6 Thymus function in these patients is reduced because of age and previous chemotherapy and, therefore, the functional maturation of T cells will take a long time. We studied development of T-cell function in auto-SCT recipients during the first 15 months after transplantation. In vitro T-cell proliferation and the cytokine production profile were determined in this prospective cohort study.
Materials and methods

Patients
Adult patients with non-Hodgkin's lymphoma or multiple myeloma and who underwent auto-SCT were included. The study was performed in the context of a larger study on the immune response to vaccination in auto-SCT recipients as reported previously. 9 In short, patients were vaccinated at 6, 8 and 14 months after auto-SCT with diphtheria, tetanus and poliomyelitis (DTP) vaccine (three doses), tetanus toxoid (TT) conjugated Haemophilus influenzae (Hib) vaccine (three doses) and a combination of pneumococcal conjugate vaccine (two doses) and pneumococcal polysaccharide vaccine (one dose). Patients with recurrence of tumor or re-introduction of chemotherapy within 6 months after auto-SCT were excluded. All patients gave written informed consent. The study was approved by the Medical Ethical Committees of the participating hospitals.
The normal controls consisted of healthy hospital personnel aged 28-61 years (median 37 years). All of the controls were vaccinated during childhood with TT as part of the national childhood vaccination schedule.
T-cell proliferation, cytokine determination and lymphocyte subsets Blood samples were collected at 6, 9 and 15 months after transplantation, which was before, after two and after three vaccinations, respectively. Heparinized peripheral blood was diluted 1:1 in RPMI-1640 (Invitrogen Life Technologies, Carlsbad, CA, USA) containing L-glutamine (2 mM) (Invitrogen Life Technologies), penicillin (100 U/ml)/streptomycin (100 mg/ml) (Invitrogen Life Technologies) and supplemented with 10% heat-inactivated fetal calf serum and mononuclear cells were isolated by density gradient centrifugation over Ficoll-Hypaque (Pharmacia, Uppsala, Sweden). The cells were washed two times, mixed with 10% DMSO (1:2, v/v) and frozen at À801C until use. Mononuclear cells (0. 4 Â 10 5 ) were cultured in triplicate in 200 ml volumes (RPMI-1640, supplemented with 20% (v/v) heatinactivated human AB serum) in 96-well round-bottom culture plates (Nunc, Wiesbaden, Germany) at 371C in 5% CO 2 with 100% relative humidity. Cells were stimulated with phytohaemagglutinin (PHA; 35 mg/ml), with a combination of 0.4 mg/ml anti-CD2 and 1 mg/ml anti-CD28 monoclonal antibodies (mAbs) (both obtained from BD Pharmingen, Erembodegem, Belgium), or with 1.5 mg/ml TT (National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands). Cells were cultured for 6 days, the last 12 h in the presence of 0.5 mCi (19 kBq) 3 H-thymidine (ICN Biomedicals, Amsterdam, The Netherlands). Cells were harvested by standard procedures, and the incorporated radioactivity was measured by liquid scintillation counting and expressed as c.p.m. Directly before the addition of 3 H-thymidine, 50 ml culture supernatant was removed and stored at À801C.
Cytokines were detected in supernatants by applying a multiplex immunoassay (Bioplex 100, Biorad, Hercules, CA, USA) using a procedure that has been described in detail previously. 12 For our purpose, IL-1a, IL-1b, IL-6 and IL-8 (CXCL-8) were measured as proinflammatory cytokines and chemokines, IL-2, IFN-g and tumour-necrosis factor-a (TNF-a) as Th1 cytokines. Furthermore, IL-4, IL-5 and IL-13 were measured as representative Th2 cytokines and IL-10 as a regulatory cytokine. 13, 14 Lymphocyte subsets were determined by immunophenotyping using the following mAbs: anti-CD3 (conjugated to Peridinin chlorophyll protein, PerCP), anti-CD4 (Allo phycocyanin, APC), anti-CD8 (phycoerythrin, PE), anti-CD45RA (fluorescein isothiocyanate) and anti-CD45RO (PE). The mAbs were added to 100 ml cell suspension and incubated for 30 min at room temperature. After washing, cells were resuspended in 200 ml phosphate-buffered saline and flow cytometric analysis (FACS Calibur, Becton Dickinson, San Jose, CA, USA) was performed within 4 h.
Statistical analyses
Differences between pre-and post-vaccination cytokine levels and thymidine incorporation were assessed by using a Wilcoxon-signed rank test. A P-value of o0.05 was considered statistically significant.
Results
Patients
Fifteen patients (10 men, 5 women) with a mean age of 58 years (range 43-68 years) were included. Haematological diagnosis was multiple myeloma in 12 patients and nonHodgkin's lymphoma in three patients. Two patients (both suffering from multiple myeloma) developed recurrence of disease, necessitating chemotherapy and were subsequently excluded from analysis. The study was performed in three teaching hospitals in The Netherlands. Identical mobilization and conditioning protocols were used at each study location. Stem cell mobilization was performed with CAD (cyclophosphamide, adriamycin and dexamethasone) plus G-CSF for patients with multiple myeloma and with DHAP (cisplatin, cytarabine and dexamethasone) plus G-CSF for patients with NHL. Patients with multiple myeloma received high-dose melphalan (cumulative dose 200 mg/m 2 ) as conditioning therapy, whereas patients with NHL received the BEAM regimen (cumulative doses: 300 mg/m 2 BCNU, 800 mg/m 2 Ara-C, 800 mg/m 2 VP16, 140 mg/m 2 melphalan). The patients were transplanted with a mean of 9.61 Â 10 6 CD34 þ cells per kg body weight (range: 2.40-34.90). The autologous stem cell grafts were unselected. After SCT, no G-CSF was administered.
Reconstitution of cellular immunity was studied by quantitative and qualitative T-lymphocyte analysis. At 6 months, after auto-SCT, levels of CD3 þ T-lymphocytes were within the normal range. The mean CD4/CD8 ratio was 0.54 at 6 months and, although consistently increasing, remained subnormal during the whole study period. Moreover, while levels of CD45RO þ cells were in the normal range at 6 months post-transplantation, levels of CD45RA þ cells were persistently low at 6 and 15 months after transplantation (Table 1) .
T-cell proliferation
Results of determination of in vitro T-cell proliferative capacity are shown in Figure 1 . The proliferative response to stimulation with CD2 þ CD28 mAbs or with PHA increased between 6 and 15 months after auto-SCT. PHA-stimulated T-cell proliferation was significantly lower in patients compared to healthy controls at all time points, whereas CD2 þ CD28 stimulated T-cell proliferation was not significantly different in patients compared to healthy controls.
In vitro cytokine profile Figure 2 shows levels of T helper-1 (Th1) cytokines (IL-2, IFN-g and TNF-a) in supernatants of PBMC stimulated with CD2 þ CD28 mAbs and PHA at 6, 9 and 15 months post-transplantation. From 6 to 15 months after transplantation, an increase in IL-2, TNF-a and IFN-g production was found (P-value: IL-2 0.036 and 0.051, TNF-a 0.036 and 0.021 and IFN-g 0.05 and 0.021 for CD2 þ CD28 and PHA, respectively). However, although levels of IL-2 were relatively high in patients compared to controls, levels of IFN-g and TNF-a were strikingly lower in patients compared to healthy controls. Levels of T helper-2 (Th2) cytokines (IL-5 and IL-13) are depicted in Figure 3 . IL-5 and IL-13 levels increased from 6 to 15 months after transplantation (P-value: IL-5 0.036 and 0.038, IL-13 0.327 and 0.028 for CD2 þ CD28 and PHA, respectively). Levels of the Th2 cytokine IL-4 were also determined, but were very low (mean levels 23.8 and 2.6 pg/ ml at 15 months after transplantation for CD2 þ CD28 and PHA, respectively). At 15 months after transplantation, levels of IL-5 and IL-13 were significantly higher in patients than in healthy controls.
Levels of the regulatory cytokine IL-10 are shown in Figure 4 . IL-10 levels significantly increased from 6 to 15 months after transplantation (P-value: 0.036 and 0.028 for CD2 þ CD28 and PHA, respectively).
Relatively low levels of the proinflammatory cytokines IL-1a, IL-1b, IL-6 and the chemokine IL-8 were found (data not shown). This is probably related to the fact that supernatants were harvested after 6 days of culture, while these proinflammatory cytokines are predominantly secreted during the first 24-48 h of cell culture.
In vitro stimulation of mononuclear cells with CD2 þ CD28 mAbs or with PHA induces polyclonal T-cell activation. For extrapolation to the in vivo situation, the response pattern to antigen-specific T-cell activation is more relevant. Because all patients participated in our vaccination study consisting of three doses of vaccination with DTP and TT-conjugated Hib vaccine, we used TT to assess antigenspecific in vitro cytokine production. TT-stimulated T-cell proliferation significantly increased from 6 to 15 months after transplantation (Table 2 ; P-value 0.028 for 15 months versus 6 months). Also, TT-stimulated production of IL-2, TNF-a, IL-5, IL-13 and IL-10 significantly increased from 6 to 15 months after auto-SCT, that is, after three vaccinations with DTP and TT-conjugated Hib vaccine (Table 2 ; P-values for 15 months versus 6 months were 0.017, 0.046, 0.028, 0.028 and 0.017 for IL-2, TNF-a, IL-5, IL-13 and IL-10, respectively). At 9 and 15 months after transplantation, the TT-induced Th2 cytokines IL-5 and IL-13 in our patients were at or above the levels induced in supernatants of PBMC cultures of healthy adults. Th1 cytokine induction was variable: activation with TT induced significant amounts of IL-2 at 9 and 15 months after transplantation (that is, after one and two doses of DTP and TT-conjugated Hib vaccine). Activation with TT however failed to induce IFNg, even at 15 months after transplantation (that is, after three doses of DTP and TT-conjugated Hib vaccine).
Discussion
In this study, cellular immune function in auto-SCT recipients was investigated by measuring in vitro T-cell proliferation and the cytokine production profile. We found ongoing restoration of T-cell proliferation and cytokine production during the first 15 months after auto-SCT. Cellular immune function in terms of T-cell proliferation has been studied previously in auto-SCT recipients. T-cell proliferation responses were suppressed 3-12 months post-transplantation in patients with breast cancer or amyloidosis undergoing auto-SCT. 16, 17 Studies regarding cytokine production after auto-SCT show conflicting results. Te Boekhorst et al.
18 compared T-lymphocyte reconstitution in T-cell-depleted versus unselected auto-SCT in patients with multiple sclerosis and haematological malignancies, respectively. They found normal intracellular production of IFN-g, IL-2 and TNF-a from 2 months post-auto-SCT onwards without significant differences between both groups. Guillaume et al. 19 studied cellular immune reconstitution in 66 patients receiving auto-SCT. In 41 patients with a medium follow-up of 50 days post-transplantation, low levels of IL-3, IL-4, IFN-g, IL-2 and IL-10 were found, while in 25 patients with a median follow-up of 654 days levels of these cytokines were Thymidine incorporation (c.p.m.) Figure 1 In vitro T-cell proliferation. In vitro T-cell proliferation in patients at 6, 9 and 15 months after auto-SCT and in healthy controls: CD2 þ CD28 (filled columns) and PHA-stimulated cultures (hatched columns).
comparable to healthy controls. Singh et al. 20 described low mRNA expression of Th1 cytokines IL-2, IFN-g and TNF-a and normal mRNA expression of Th2 cytokine IL-4, 12 months after auto-SCT in patients with nonHodgkin's lymphoma. Levels of IL-10 were relatively high during the first 100 days after transplantation, but normal- ized thereafter. However, cellular function as measured by in vitro T-cell proliferation was depressed during the entire study period. They suggested that the initially high levels of IL-10 might explain the cellular immune dysfunction. IL-10 inhibits cytokine production and antigen stimulated T-cell proliferation by a direct negative effect on T-lymphocytes as well as indirectly by downregulation of class II MHC expression and thus antigen-presenting cells. 21 In our study, however, a strong suppressive effect of IL-10 on T-cell proliferation seems unlikely, since increases in IL-10 production were paralleled by significant increases in T-cell proliferation.
In the current study, a robust production of Th2 cytokines IL-5 and IL-13 was found 15 months after transplantation, while production of the Th1 cytokines IFN-g and TNF-a remained low during the entire study period. Th2 cytokines are important for regulation of the humoral immune response. 13, 22 In a previous report, we described significant increases in quantitative and qualitative antibody responses to recall antigens following auto-SCT in this group of patients. 9 Our current results show superior recovery of antigen-stimulated production of the prototype Th2 cytokines IL-5 and IL-13 as compared to that of the Th1 cytokine IFN-g. Schlenke et al. 23 also found impaired intracellular production of IFN-g during the first 12 months after auto-SCT. In mice, pre-treatment of donors with G-CSF resulted in decreased secretion of IFNg. 24, 25 Sloand et al. 26 confirmed this decreased production of IFN-g after administration of G-CSF in humans. Although our patients did not receive G-CSF in the transplantation period, the stem cell mobilization regimen (performed weeks to months before transplantation) included the administration of G-CSF. Thus, the low levels of IFN-g may be attributed in part to the G-CSF pre-treatment.
A relatively high incidence of viral infections is observed for a prolonged period after auto-SCT. 17, 18 For instance, varicella zoster virus (VZV) infections are seen in approximately 50% of bone marrow transplant recipients, until 18 months after transplantation. 27 Th1 cytokines, and in particular IFN-g, are important for development of cytotoxic effector T-lymphocytes. 13, 28, 29 A deficient production of Th1 cytokines, therefore, might contribute to the occurrence of viral infections after auto-SCT. Because the currently available VZV vaccine is a live attenuated vaccine with potentially serious side effects in patients with impaired immune function, vaccination with VZV vaccine is not recommended in auto-SCT recipients during the first 2 years. Therefore, we vaccinated our patients with bacterial vaccines (DTP, Hib and pneumococcal vaccines) following the general guidelines. 30, 31 Since our patients were vaccinated with TT-containing vaccines, we used TT as antigenic stimulus in our cell cultures. However, future studies concerning in vitro CMV or VZV-stimulated cytokine production are necessary to elucidate a possible association between deficient production of Th1 cytokines and viral infections after auto-SCT.
In conclusion, our data show ongoing recovery of cellular immunity during the first 15 months after auto-SCT, which is reflected in an increase in in vitro T-cell proliferation and restoration of cytokine production. Production of Th1 cytokines IFN-g and TNF-a, however, remains severely impaired during this period. Figure 4 Production of IL-10. Mean levels ( þ s.e.m.) of IL-10 in CD2 þ CD28 (filled columns) or PHA (hatched columns) stimulated cultures set up at 6, 9 and 15 months after auto-SCT (n ¼ 13) and in controls (n ¼ 7). Cytokine concentrations in cultures in medium only, was o0.4 pg/ml at all time points. Table 2 Tetanus toxoid-stimulated cytokine production and T-cell proliferation Mean TT-stimulated cytokine levels (pg/ml7s.e.m.) and T-cell proliferation (thymidine incorporation in c.p.m.7s.e.m.) are given for cultures with PBMC obtained at 6, 9 and 15 months after auto-SCT (that is before and after two and three vaccinations, respectively; n ¼ 13) and in healthy controls (n ¼ 9). *P-values of cytokine levels of patients at 15 months versus controls are given.
